美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

三倍做多標普生物-Direxion

261.30

-4.7000-1.77%

盤後：261.300.00000.00%19:58 EDT

成交量：22.74萬

成交額：6,097.03萬

市值：4.90億

市盈率：- -

高：278.96

開：273.29

低：261.30

收：266.00

52周最高：341.93

52周最低：74.95

股本：187.45萬

流通股本：187.45萬

量比：0.94

換手率：12.13%

股息：1.00

股息率：0.38%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

中國生物製藥(01177.HK)：TQB6426「GPC3 ADC」臨床試驗申請獲FDA批准

中國生物製藥：附屬公司正大天晴自主研發的國家1類新藥TQB6426臨床試驗申請獲FDA批准

American Healthcare REIT（AHR）宣佈完成收購八個高端養老社區涉資近7億美元

醫療保健板塊綜述：市場快訊

中國生物製藥早盤升逾4% TQB6426獲FDA批准開展臨床

這些女性在休產假期間被解僱。是的，這合法，而且可能比你想象的更常見

环球市场播报

醫療保健板塊市場快訊匯總

聯合治療（UTHR）霧化吸入劑Tyvaso擴大適應症申請獲FDA受理

翰宇藥業(300199.SZ)：坪山分公司通過美國FDA現場檢查

翰宇藥業：坪山分公司第二次通過FDA現場檢查

醫療保健板塊動態：市場快訊匯總

美股異動 | 禮來(LLY.US)漲1.69% 阿爾茨海默病血液檢測獲FDA批准

美股異動 | 禮來(LLY.US)漲1.69% 阿爾茨海默病血液檢測獲FDA批准

FDA批准替爾泊肽用於降低T2D成人患者心血管事件風險

仙琚製藥(002332.SZ)：黃體酮陰道片獲得美國FDA註冊申請受理

仙琚製藥：100mg黃體酮陰道片ANDA獲美國FDA受理

百濟神州：PD-1抗癌藥降價加入美國公共醫療保險計劃今後上市創新藥均將執行最惠國定價

每日经济新闻

迪哲醫藥：舒沃哲新增適應症上市申請獲美國FDA受理

9月1日起，烏魯木齊靈活就業人員可參加生育保險！

新疆949交通广播

美國FDA批准胰腺癌突破性藥物獨立藥企Revolution Medicines迎里程碑

环球市场播报

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/LABU/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多標普生物-Direxion","latestPrice":261.3,"timestamp":1789156800000,"preClose":266,"halted":0,"volume":227375,"hourTrading":{"tag":"盘后","latestPrice":261.3,"preClose":261.3,"latestTime":"19:58 EDT","volume":728,"amount":191085.6107,"timestamp":1789171090575,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.017669172932330786,"floatShares":1874486,"shares":1874486,"eps":0,"marketStatus":"休市中","change":-4.7,"latestTime":"09-11 16:00:00 EDT","open":273.29,"high":278.9613,"low":261.3,"amount":60970299.293749996,"amplitude":0.066396,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":266,"sharesOutstanding":3074486,"nav":261.603,"aum":516531253.77,"dividendRate":0.003844,"bidAskSpread":0.003144,"preHourTrading":{"tag":"盘前","latestPrice":274.69,"preClose":266,"latestTime":"09:28 EDT","volume":2486,"amount":673283.80262,"timestamp":1789133308224,"change":8.69,"changeRate":0.032669,"amplitude":0.031541},"postHourTrading":{"tag":"盘后","latestPrice":261.3,"preClose":261.3,"latestTime":"19:58 EDT","volume":728,"amount":191085.6107,"timestamp":1789171090575,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9397711565267511,"impliedVol":0.8728,"impliedVolPercentile":0.3227},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1874486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.9397711565267511,"shares":1874486,"dividePrice":1.0045,"high":278.9613,"amplitude":0.066396,"preClose":266,"low":261.3,"week52Low":74.95,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":261.3,"eps":0,"divideRate":0.003844,"volume":227375,"delay":0,"ttmEps":0,"open":273.29,"prevYearClose":159.39,"prevWeekClose":303.55,"prevMonthClose":296.31,"prevQuarterClose":292.1,"fiveDayClose":305.86,"twentyDayClose":273.91,"sixtyDayClose":184.63},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664872828","title":"中國生物製藥(01177.HK)：TQB6426「GPC3 ADC」臨床試驗申請獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872828","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664872828?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 20:42","pubTimestamp":1788439353,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBQ","LABU","MDTX","PSYK","BK4585","BK4588","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874071","title":"中國生物製藥：附屬公司正大天晴自主研發的國家1類新藥TQB6426臨床試驗申請獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874071","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874071?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 20:41","pubTimestamp":1788439284,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4585","BMED","BK4588","MDTX","IBBJ","IBBQ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664791008","title":"American Healthcare REIT（AHR）宣佈完成收購八個高端養老社區 涉資近7億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664791008","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664791008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 19:17","pubTimestamp":1788434240,"startTime":"0","endTime":"0","summary":"金吾财讯 | American Healthcare REIT 宣布以约6.96亿美元的总价收购了八个A级高端老年住宅社区，一举打入供应受限的美国东北部养老地产核心市场。据悉，AHR在完成交易后，将另外两项非核心社区的购买协议以成本价转让给了另一家机构投资者。而随着本次收购落地，AHR在2026年年内完成的总投资额已突破20亿美元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/Nzg4NjU0MjU3NDIxMDY0.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Nzg4NjU0MjU3NDIxMDY0.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305693","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AHR","IVRA","BK4581","CFA.SI","RNTY","MDIV","BK4225","DFRA","BK6142","JJJ.SI","BK4588","PSCF","GLS.SI","RJMG","SRT.SI","YLDW","IQRA","BPRE","8C8U.SI","XLV","SRU.SI","CLR.SI","XBI","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195881897","title":"醫療保健板塊綜述：市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1195881897","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195881897?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:23","pubTimestamp":1788423797,"startTime":"0","endTime":"0","summary":"澳大利亚国家老年人护理分类起步价上调2.55%，这一幅度远低于Regis Healthcare及其他住宅式老年护理服务商所面临的成本通胀压力。瑞银分析指出，2026财年医疗行业工资通胀率已达3.8%。\"该机构将Regis的目标股价从每股6.75澳元下调至5.95澳元，但维持中性评级。该股目前下跌27%，报4.31澳元。诺华股价下跌0.75%，罗氏股价上涨0.8%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","BK4581","XLV","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238088","title":"中國生物製藥早盤升逾4% TQB6426獲FDA批准開展臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238088","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664238088?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 10:28","pubTimestamp":1788402480,"startTime":"0","endTime":"0","summary":"模拟交易客户端中国生物制药早盘涨近5%。截至发稿，股价上涨4.47%，现报5.50港元，成交额1.54亿港元。中国生物制药旗下正大天晴自主研发的创新型GPC3抗体药物偶联物TQB6426，于近日获得美国食品药品监督管理局临床试验默认许可，拟用于晚期恶性肿瘤治疗。至此，TQB6426拿下中美两大核心医药市场临床准入资质，成为公司创新药全球化开发的重要里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-03/doc-iniqpeka1141170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01177","BK1589","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YR35.GBP","LABU","BK1521","BK4588","BK4585","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664843670","title":"這些女性在休產假期間被解僱。是的，這合法，而且可能比你想象的更常見","url":"https://stock-news.laohu8.com/highlight/detail?id=2664843670","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664843670?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 00:57","pubTimestamp":1788368220,"startTime":"0","endTime":"0","summary":"妇女与家庭伙伴关系的高级研究员凯瑟琳·加拉格尔·罗宾斯表示，很难说女性在产假期间被解雇有多普遍，但一些指标表明这是一个持续存在的问题。近期数据显示，女性承担了失业的主要冲击。对于处于离职生育和照顾新生儿这一脆弱地位的女性来说，在此期间失业的可能性感觉像一个永远笼罩的威胁。美国确实存在法律保护工人免受因休产假或与怀孕或照顾新生儿相关的其他便利安排而受到歧视。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-03/doc-iniqnieq7440478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["DEI","BK4194","BK4223","XLV","XBI","BK4581","BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190612977","title":"醫療保健板塊市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1190612977","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190612977?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 00:26","pubTimestamp":1788366410,"startTime":"0","endTime":"0","summary":"该分析师在研究报告中写道，公司对盈利能力的展望比市场预期更为乐观。Equita SIM维持对该股的买入评级。截至发稿，股价报157.95欧元，下跌1%。2208 ET - CIMB证券分析师Chun Sung Oong在报告中表示，德里高等法院任命法务审计师追查与前Fortis发起人Malvinder Singh和Shivinder Singh相关的涉嫌资产转移事件，对IHH医疗的直接影响可能微乎其微。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","BK4581","XBI","XLV","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664814414","title":"聯合治療（UTHR）霧化吸入劑Tyvaso擴大適應症申請獲FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664814414","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664814414?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:52","pubTimestamp":1788353572,"startTime":"0","endTime":"0","summary":"金吾财讯 | 联合治疗（UTHR）宣布，美国食品药品监督管理局（FDA）已正式受理其核心产品Tyvaso（曲前列尼尔，Treprostinil）雾化吸入剂的补充新药申请，用以扩大其在美国的标签范围，拓展至特发性肺纤维化（IPF）的治疗。据官方披露，FDA预计将于2027年4月下旬完成对该项申请的审查。若该申请顺利获批，雾化Tyvaso将成为全美首个且唯一用于治疗特发性肺纤维化的吸入式抗纤维化药物，极大改善患者给药体验与疗效。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210625/YjE5NjM0NjA5NTUxNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YjE5NjM0NjA5NTUxNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305638","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","BK4585","BK4588","BK4532","UTHR","BK4139","LABU","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664153088","title":"翰宇藥業(300199.SZ)：坪山分公司通過美國FDA現場檢查","url":"https://stock-news.laohu8.com/highlight/detail?id=2664153088","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664153088?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 18:52","pubTimestamp":1788346359,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业 发布公告，公司坪山分公司于2026年6月18日至26日接受了美国食品药品监督管理局的现行药品生产质量管理规范常规监督检查。近日，公司收到了FDA签发的现场检查报告。此次检查是坪山分公司继2023年7-8月首次通过FDA批准前检查后，第二次接受FDA检查并顺利通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","BK0077","300199","BK0239","BK0028","BK0070","LABU","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664813240","title":"翰宇藥業：坪山分公司第二次通過FDA現場檢查","url":"https://stock-news.laohu8.com/highlight/detail?id=2664813240","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664813240?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 18:39","pubTimestamp":1788345598,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182230701","title":"醫療保健板塊動態：市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1182230701","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182230701?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 04:56","pubTimestamp":1788296217,"startTime":"0","endTime":"0","summary":"针对自身免疫性疾病及神经系统疾病的实验性疗法临床试验，诺华公司决定按下暂停键。此前，该试验中有三名患者不幸离世，这令投资者们心生警惕。\"与此同时，另一项关于多发性硬化症药物的独立研究传来了积极结果，受此提振，诺华股价攀升5.9%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LABU","XBI","BK4581","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664850799","title":"美股異動 | 禮來(LLY.US)漲1.69% 阿爾茨海默病血液檢測獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664850799","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664850799?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 23:35","pubTimestamp":1788276923,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，礼来涨1.69%，报1176.23美元。消息面上，礼来与罗氏联合开发的Elecsys Phospho-TauPlasma血液检测已拿到美国FDA批准，用于辅助判断55岁及以上出现认知衰退症状人群，是否存在阿尔茨海默病相关脑内淀粉样蛋白病理改变。据悉，这一诊断技术直击阿尔茨海默病治疗的现实痛点。能否实现低成本、标准化、可大规模普及的筛查手段，直接决定相关药物的患者覆盖规模，也会影响新一代阿尔茨海默病药物向更早阶段人群推广的进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664685079","title":"美股異動 | 禮來(LLY.US)漲1.69% 阿爾茨海默病血液檢測獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664685079","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664685079?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 23:35","pubTimestamp":1788276923,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664481854","title":"FDA批准替爾泊肽用於降低T2D成人患者心血管事件風險","url":"https://stock-news.laohu8.com/highlight/detail?id=2664481854","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664481854?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 21:41","pubTimestamp":1788270068,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385320","title":"仙琚製藥(002332.SZ)：黃體酮陰道片獲得美國FDA註冊申請受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385320","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664385320?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:00","pubTimestamp":1788260459,"startTime":"0","endTime":"0","summary":"智通财经APP讯，仙琚制药(002332.SZ)发布公告，公司向美国食品药品监督管理局(简称“FDA”)递交了黄体酮阴道片的ANDA注册申请，公司于近日收到美国FDA注册申请受理的通知。黄体酮阴道片适应症为辅助生殖ART黄体支持，通过补充黄体功能，支持胚胎着床与早期妊娠。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999014674.SGD","BK4585","BK4588","002332","BK0028","LABU","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385362","title":"仙琚製藥：100mg黃體酮陰道片ANDA獲美國FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664385362?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 18:51","pubTimestamp":1788259894,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664026884","title":"百濟神州：PD-1抗癌藥降價加入美國公共醫療保險計劃 今後上市創新藥均將執行最惠國定價","url":"https://stock-news.laohu8.com/highlight/detail?id=2664026884","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664026884?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 09:36","pubTimestamp":1788226577,"startTime":"0","endTime":"0","summary":"美国当地时间8月31日，美国总统特朗普宣布与9家制药企业达成全新协议，为美国民众下调处方药价格，药价对标其他发达国家的最低采购价，即“最惠国（MFN）价格”，其中包括国内创新药龙头百济神州。9月1日，百济神州对《每日经济新闻》记者表示，根据协议，百济神州将通过Medicaid项目，以约定的价格向符合条件的患者提供替雷利珠单抗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013861069086.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013861069086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","KURE","LU0228659784.USD","MEDX","159992","688235","BK1583","BK4581","BK4023","XLV","BK1500","BK4585","LU1251922891.USD","LU0828237510.HKD","LU1303224171.USD","LU1770034418.SGD","BK4588","XBI","BK1588","LABU","06160","BK1161","BK1574","ONC","LU1969619763.USD","LU0588546209.SGD","IBBQ","LU2328871848.SGD","PD","LU1169589451.USD","IPOS","BK0239","CANC","LNGR","BK4139","LU1169590202.USD","BK4526","LU0307460666.USD","LU1719994722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663776046","title":"迪哲醫藥：舒沃哲新增適應症上市申請獲美國FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2663776046","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663776046?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 15:45","pubTimestamp":1788075936,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","LABU","IPOS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663462770","title":"9月1日起，烏魯木齊靈活就業人員可參加生育保險 ！","url":"https://stock-news.laohu8.com/highlight/detail?id=2663462770","media":"新疆949交通广播","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663462770?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 15:09","pubTimestamp":1788073740,"startTime":"0","endTime":"0","summary":"灵活就业人员完成生育保险参保登记后，按照税务部门征管规定按月申报缴纳生育保险费，缴费渠道、征管方式与职工基本医疗保险一致，由税务部门统一征收。待遇保障方面，灵活就业人员连续缴纳职工医保满6个月，即可享受生育医疗费用报销。生育津贴方面，参加生育保险的灵活就业人员生育相关手术发生时，生育保险连续缴费满10个月，可按月申领生育津贴；缴费不足10个月的，缴满10个月后再申领。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-08-30/doc-iniqaqpr2826938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XLV","BK4585","BK4581","BK4588","XBI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662061828","title":"美國FDA批准胰腺癌突破性藥物 獨立藥企Revolution Medicines迎里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662061828","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662061828?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 18:15","pubTimestamp":1787912149,"startTime":"0","endTime":"0","summary":"Revolution Medicines历时近十年持续攻关，在500人规模临床试验中获得积极数据，最终获得监管批准。为完成交易，戈德史密斯与Warp Drive最大股东赛诺菲协商，将后者持有的Warp Drive多数股权置换为Revolution Medicines的部分股权，最终达成协议。在正式获批前，美国食品药品管理局已通过同情用药项目允许Revolution Medicines提前约四个月向患者分发药物，截至获批时已有超过2000名患者纳入该项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-28/doc-inipwhrt5845666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["IDNA","IE0002141913.USD","BBH","LU0889565916.HKD","BK4585","IE0009354923.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LABU","RVMD","IE00B2B36J28.USD","CANC","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4139","IE00BJT1NW94.SGD","BK4588","LU0320765992.SGD","PTH","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}